ASCRS 2020: Intraocular dexamethasone, moxifloxacin vs topical regimen

Ophthalmology Times' David Hutton speaks with John A. Hovanesian, MD, about the highlights of his presentation on patient-reported tolerance and satisfaction with intraocular administration of dexamethasone and moxifloxacin versus a topical regimen, during the 2020 ASCRS virtual meeting.


See more ASCRS conference coverage here 

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.